Treatment of Breast Cancer‐Related Lymphedema with Adipose‐Derived Regenerative Cells and Fat Grafts: A Feasibility and Safety Study

Autor: Søren P. Sheikh, Charlotte Harken Jensen, Navid Mohamadpour Toyserkani, Jens Ahm Sørensen, Ditte Caroline Andersen
Jazyk: angličtina
Rok vydání: 2017
Předmět:
0301 basic medicine
Vascular Regeneration
medicine.medical_treatment
Regenerative medicine
law.invention
0302 clinical medicine
Human Clinical Article
Mesenchymal Stem Cell Transplantation/adverse effects
Randomized controlled trial
law
Adipose-derived regenerative cells
Tissue Transplantation/adverse effects
Lymphedema
Cells
Cultured
lcsh:R5-920
Breast Cancer Lymphedema/therapy
lcsh:Cytology
Adipose-Derived Regenerative Cells
General Medicine
Middle Aged
Post‐surgical Repair
Adipose‐derived regenerative cells
Adipose Tissue
030220 oncology & carcinogenesis
Tissue Transplantation
Female
Adipose Tissue/cytology
Stem cell
lcsh:Medicine (General)
Adult
medicine.medical_specialty
Adipose Stem Cells/VSF
Breast Cancer Lymphedema
Mesenchymal Stem Cell Transplantation
Human Clinical Articles
03 medical and health sciences
medicine
Humans
Clinical Trials
Fat graft Authored by a member of
lcsh:QH573-671
Adverse effect
Fat graft
Aged
business.industry
Mesenchymal stem cell
Cell Biology
medicine.disease
Surgery
030104 developmental biology
Liposuction
Feasibility Studies
business
Developmental Biology
Zdroj: Stem Cells Translational Medicine, Vol 6, Iss 8, Pp 1666-1672 (2017)
Toyserkani, N M, Jensen, C H, Andersen, D C, Sheikh, S P & Sørensen, J A 2017, ' Treatment of breast cancer-related lymphedema with adipose-derived regenerative cells and fat grafts : A feasibility and safety study ', Stem Cells Translational Medicine, vol. 6, no. 8, pp. 1666-1672 . https://doi.org/10.1002/sctm.17-0037
Stem Cells Translational Medicine
ISSN: 2157-6564
2157-6580
Popis: Breast cancer-related lymphedema (BCRL) is a debilitating late complication with a lack of treatment opportunities. Recent studies have suggested that mesenchymal stromal cells can alleviate lymphedema. Herein, we report the results from the first human pilot study with freshly isolated adipose-derived regenerative cells (ADRC) for treating lymphedema with 6 months follow-up. Ten BCRL patients were included. ADRC was injected directly into the axillary region, which was combined with a scar-releasing fat graft procedure. Primary endpoints were change in arm volume. Secondary endpoints were change in patient reported outcome and safety. The study is registered with ClinicalTrials.gov (NCT02592213). During follow-up, a small volume reduction was noted but was not significant. Five patients reduced their use of conservative management. Patient-reported outcomes improved significantly over time. ADRCs were well tolerated and only minor transient adverse events related to liposuction were noted. In this pilot study, a single injection of ADRC improved lymphedema based on patient-reported outcome measures, and there were no serious adverse events in the 6 months follow-up period. In addition, half of the patients reduced their use of conservative management. ADRC therapy is a promising interventional therapy for alleviating lymphedema, but results need to be confirmed in randomized clinical trials.
Databáze: OpenAIRE
Externí odkaz: